Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth

Executive Summary

Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.

Advertisement

Related Content

Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products
Generic Industry Consolidation Illustrated In ANDA Holder List
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Birth Of A Giant: A Timeline Of Teva And Allergan's Generics Business
Teva, Allergan Probably Won't Need More Divestments To Get FTC Approval
FTC's Generic Market Analysis Forcing Divestures Even In Diverse Categories

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118851

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel